Last updated: February 19, 2026
Who are the leading suppliers of Doxylamine Succinate?
Doxylamine Succinate is primarily supplied by chemical and pharmaceutical manufacturers globally. Market data indicates that the drug is produced by several multinational companies, with the top suppliers concentrated in China, India, and Europe. Entry barriers are moderate due to regulatory approvals, manufacturing standards, and economies of scale.
Major suppliers and manufacturing regions
| Company Name |
Country |
Estimated Production Capacity |
Key Markets Served |
Notable Certifications |
| Zhejiang Tianyuan Bio-Pharmaceutical Co. |
China |
500 kg/month |
Asia, Europe |
GMP, ISO 9001, ISO 14001 |
| Ajanta Pharma Ltd. |
India |
350 kg/month |
India, Middle East |
WHO-GMP, ISO 9001, ISO 14001 |
| UniPharma & Chemical Co. |
Greece |
120 kg/month |
Europe, North America |
GMP, ISO 9001 |
| Qingdao Eastchem Co. |
China |
400 kg/month |
Asia, Africa |
GMP, ISO 9001 |
| Shanghai Ra-Qi Chemical |
China |
300 kg/month |
Asia, South America |
GMP, ISO 9001 |
Note: Production capacities are estimates, based on industry reports from 2022.
Sources and supply chain considerations
Suppliers generally source raw materials from chemical intermediates produced in China and India. Many companies hold Good Manufacturing Practice (GMP) certifications to meet pharmacopeial standards, enabling global export. Regulatory approvals, notably from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), influence supply continuity.
Regulatory and quality standards
Suppliers of Doxylamine Succinate adhere to various standards:
- GMP: Ensures manufacturing quality meets pharmacopeial specifications.
- ISO 9001 & ISO 14001: Quality management and environmental standards.
- Certificates of Analysis (CoA): Typically provided to affirm purity (>99%).
Suppliers operating in China and India encounter different regulatory environments, which can impact lead times and compliance documentation for global markets.
Market entry and risks
Barriers to entry include:
- Regulatory approval processes that can take 12–24 months.
- Patents or exclusivity rights held by other pharmaceutical firms, although Doxylamine Succinate itself is available as a generic.
- Quality validation through audits and inspections.
Risks involve supply disruptions due to geopolitical tensions, supply chain interruptions, or changes in regulatory practices.
Market trends and future outlook
The global market for antihistamines and sleep aids supports demand for Doxylamine Succinate. Suppliers expanding capacity are primarily based in China and India due to cost advantages. Increased regulatory scrutiny may affect supplier operations, especially for companies expanding into European and North American markets.
Key Takeaways
- The primary suppliers of Doxylamine Succinate are companies in China, India, and Greece.
- Capacity estimates suggest a global monthly supply of over 1 kilogram per manufacturer.
- Regulatory standards such as GMP and ISO are critical for global distribution.
- Raw material sourcing heavily favors Chinese and Indian chemical intermediates.
- Market growth depends on pharmaceutical demand for sleep aids and antihistamines, with supply chain risks linked to geopolitical and regulatory factors.
FAQs
1. Which companies dominate Doxylamine Succinate supply?
Zhejiang Tianyuan Bio-Pharmaceutical, Ajanta Pharma, Qingdao Eastchem, and UniPharma are leading suppliers.
2. Are there regional differences in supplier quality standards?
Yes. Chinese suppliers generally adhere to GMP, but regulatory enforcement varies. Indian and European suppliers tend to have stricter quality control measures aligned with international standards.
3. What is a typical lead time for new supplier qualification?
The process usually takes 12 to 24 months, involving regulatory approvals and manufacturing validations.
4. How does raw material sourcing impact supply security?
Most chemical intermediates are sourced from China and India, which can expose the supply chain to regional disruptions.
5. What are the key regulatory considerations for suppliers?
Compliance with GMP, obtaining necessary certifications, and meeting pharmacopeial standards are essential for market access in regulated countries.
References
[1] PharmaCompass. (2022). Doxylamine Succinate Market Overview. Retrieved from https://www.pharmacompass.com
[2] Indian Chemical Industry Report. (2022). Chemical Intermediates for Pharmaceuticals. Ministry of Chemicals and Fertilizers, Government of India.
[3] European Medicines Agency. (2022). Good Manufacturing Practice Inspections. EMA Reports.
